Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
NCT ID: NCT04292340
Last Updated: 2020-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
15 participants
OBSERVATIONAL
2020-02-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19
NCT04425915
Convalescent Plasma as a Possible Treatment for COVID-19
NCT04442191
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
NCT04428021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants received anti-SARS-CoV-2 inactivated convalescent plasma
* Written the informed consent.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Public Health Clinical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hongzhou Lu
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongzhou Lu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Shanghai Public Health Clinical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jun Chen
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Anti-SARS-CoV-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.